Eşref Araç, Ihsan Solmaz, H. Akkoç, S. Dönmezdil, Zülküf Karahan, S. Kaya, Yılmaz Mertsoy, M. S. Yıldırım, N. Ekin, S. Araç, C. Demir
We aimed to investigate whether there is a predisposition to COVID-19 with ABO and Rh blood group systems This study was a retrospective study that investigate the patients admitted to our hospital between March 16 -May 20 due to Covid-19 pandemic and conducted with data revealed from the hospital Information Management System A total of 392 patients were included in this study, including 227 PCR test positive patients with blood group information in the system and 165 possible patients with CT findings in favor of Covid-19 Data from a blood group study conducted with 127091 people in our province in 2019 were used as a control group In our study, a significant increase was observed in the blood group A in patients diagnosed with Covid-19, and a decrease was found in the blood groups B, AB and especially O However, statistical analysis showed no significant difference between Covid-19 patients and healthy individuals in terms of ABO blood group system When analyzed in terms of Rh blood group system, it was found that Rh positivity was statistically significantly higher in patients with Covid-19 (p= 0 000) Our study suggests that the Rh (-) blood group is protective and the Rh (+) blood group is predisposed to Covid 19 significantly We think that it is valuable because it is the first study to reveal the relationship between Covid-19 and blood type in our country and the only one to reveal the relationship between Covid-19 and Rh (+) in the world literature
{"title":"Association Between the Rh Blood Group and the Covid-19 Susceptibility","authors":"Eşref Araç, Ihsan Solmaz, H. Akkoç, S. Dönmezdil, Zülküf Karahan, S. Kaya, Yılmaz Mertsoy, M. S. Yıldırım, N. Ekin, S. Araç, C. Demir","doi":"10.4999/uhod.204247","DOIUrl":"https://doi.org/10.4999/uhod.204247","url":null,"abstract":"We aimed to investigate whether there is a predisposition to COVID-19 with ABO and Rh blood group systems This study was a retrospective study that investigate the patients admitted to our hospital between March 16 -May 20 due to Covid-19 pandemic and conducted with data revealed from the hospital Information Management System A total of 392 patients were included in this study, including 227 PCR test positive patients with blood group information in the system and 165 possible patients with CT findings in favor of Covid-19 Data from a blood group study conducted with 127091 people in our province in 2019 were used as a control group In our study, a significant increase was observed in the blood group A in patients diagnosed with Covid-19, and a decrease was found in the blood groups B, AB and especially O However, statistical analysis showed no significant difference between Covid-19 patients and healthy individuals in terms of ABO blood group system When analyzed in terms of Rh blood group system, it was found that Rh positivity was statistically significantly higher in patients with Covid-19 (p= 0 000) Our study suggests that the Rh (-) blood group is protective and the Rh (+) blood group is predisposed to Covid 19 significantly We think that it is valuable because it is the first study to reveal the relationship between Covid-19 and blood type in our country and the only one to reveal the relationship between Covid-19 and Rh (+) in the world literature","PeriodicalId":49402,"journal":{"name":"Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi","volume":"25 1","pages":"81-86"},"PeriodicalIF":0.6,"publicationDate":"2020-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74096880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In this image a macrophage in cerebrospinal fluid (CSF) is caught doing what it does best; cleansing the environment of objects that don’t belong. The patient, a 6-month-old girl, initially presented with choking and feeding difficulty. Brain MRI revealed a large tumour in the right posterior fossa, originating from the inferior aspect of the right cerebellar hemisphere. She underwent surgery to remove the tumour a few days before the CSF was sampled. Histologic examination confirmed the diagnosis of Atypical Teratoid Rhabdoid Tumor. The macrophage is seen stretching its pseudopods –like a well-trained athlete reaching out to make a catch– to grab a red blood cell (RBC) (short arrow). Particles of digested debris from other RBCs are noted within its cytoplasm (long arrow) – evidence that this phagocytic act had been performed several times before. Macrophages, via chemotaxis, play a significant role in cleansing surgical sites by removing debris and organisms.
{"title":"A macrophage at work","authors":"B. Kahwash, S. Kahwash, G. Tan","doi":"10.4999/UHOD.171981","DOIUrl":"https://doi.org/10.4999/UHOD.171981","url":null,"abstract":"In this image a macrophage in cerebrospinal fluid (CSF) is caught doing what it does best; cleansing the environment of objects that don’t belong. The patient, a 6-month-old girl, initially presented with choking and feeding difficulty. Brain MRI revealed a large tumour in the right posterior fossa, originating from the inferior aspect of the right cerebellar hemisphere. She underwent surgery to remove the tumour a few days before the CSF was sampled. Histologic examination confirmed the diagnosis of Atypical Teratoid Rhabdoid Tumor. The macrophage is seen stretching its pseudopods –like a well-trained athlete reaching out to make a catch– to grab a red blood cell (RBC) (short arrow). Particles of digested debris from other RBCs are noted within its cytoplasm (long arrow) – evidence that this phagocytic act had been performed several times before. Macrophages, via chemotaxis, play a significant role in cleansing surgical sites by removing debris and organisms.","PeriodicalId":49402,"journal":{"name":"Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi","volume":"5 1","pages":"193-193"},"PeriodicalIF":0.6,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85009355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Y. Sağlam, Yasemin Bolukbasi, Vildan Alpan, Erkan Topkan, Steve M. Kirsner, Matthew Ballo, Joe Y. Chang, A. Bingolbali, Uğur Selek
{"title":"Küçük hücreli dışı akciğer kanserli hastaların tedavisinde hibrid volümetrik ark radyoterapi, yoğunluk ayarlı radyoterapi ve volumetrik yoğunluk ayarlı ark radyoterapisinin avantajlarını birleştirerek, hızlı, konformal ve homojen bir tedaviyi düşük doz banyosundan sakınarak yapabilmektedir: Dozimetr","authors":"Y. Sağlam, Yasemin Bolukbasi, Vildan Alpan, Erkan Topkan, Steve M. Kirsner, Matthew Ballo, Joe Y. Chang, A. Bingolbali, Uğur Selek","doi":"10.4999/UHOD.172064","DOIUrl":"https://doi.org/10.4999/UHOD.172064","url":null,"abstract":"","PeriodicalId":49402,"journal":{"name":"Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi","volume":"36 1","pages":"161-170"},"PeriodicalIF":0.6,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79981757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rezwan Islam, Mahbubur Rahman, M. A. H. Mian, Hilmi Ege, Douglas Reding, Abdus Shakoor, Hong Liang, Richard J. Mercier
Rituximab is an anti-CD20 monoclonal antibody that has demonstrated efficacy in patients with indolent and aggressive forms of non-Hodgkin’s lymphoma and has become part of the standard therapy for patients with B-cell malignancies. The study was designed to examine if rituximab increases the risk to develop non-neutropenic infection (NNI). Medical records of 202 patients diagnosed as follicular lymphoma or small lymphocytic lymphoma were reviewed. Negative binomial regression was used to estimate relative risk (RR) of NNI. Rituximab (n= 41) and non-rituximab (n= 161) groups had a total of 31.636 and 195.691 reviewed patient days, and recorded a total of 67 and 154 infections, respectively. Negative binomial regression analysis revealed significant effects for the treatment (rituximab vs. non-rituximab) and age (p< 0.01). The RRs of viral and bacterial NNI for rituximab group compared to nonrituximab group were 3.33 and 2.60, respectively; while the RRs for one year increment of age were 1.03 and 1.04, respectively. The time-to-first viral and bacterial NNI for rituximab group were significantly faster than non-rituximab group. Rituximab may increase the risk of NNI in patients with follicular lymphoma or small lymphocytic lymphoma.
{"title":"foliküler lenfomali{dotless} ve küçük lenfositik lenfomali{dotless} hastalarda nötropenik olmayan enfeksiyon i{dotless}nsidansi{dotless}: Rituximab tedavisinin etkisi","authors":"Rezwan Islam, Mahbubur Rahman, M. A. H. Mian, Hilmi Ege, Douglas Reding, Abdus Shakoor, Hong Liang, Richard J. Mercier","doi":"10.4999/UHOD.11035","DOIUrl":"https://doi.org/10.4999/UHOD.11035","url":null,"abstract":"Rituximab is an anti-CD20 monoclonal antibody that has demonstrated efficacy in patients with indolent and aggressive forms of non-Hodgkin’s lymphoma and has become part of the standard therapy for patients with B-cell malignancies. The study was designed to examine if rituximab increases the risk to develop non-neutropenic infection (NNI). Medical records of 202 patients diagnosed as follicular lymphoma or small lymphocytic lymphoma were reviewed. Negative binomial regression was used to estimate relative risk (RR) of NNI. Rituximab (n= 41) and non-rituximab (n= 161) groups had a total of 31.636 and 195.691 reviewed patient days, and recorded a total of 67 and 154 infections, respectively. Negative binomial regression analysis revealed significant effects for the treatment (rituximab vs. non-rituximab) and age (p< 0.01). The RRs of viral and bacterial NNI for rituximab group compared to nonrituximab group were 3.33 and 2.60, respectively; while the RRs for one year increment of age were 1.03 and 1.04, respectively. The time-to-first viral and bacterial NNI for rituximab group were significantly faster than non-rituximab group. Rituximab may increase the risk of NNI in patients with follicular lymphoma or small lymphocytic lymphoma.","PeriodicalId":49402,"journal":{"name":"Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi","volume":"34 1","pages":"220-226"},"PeriodicalIF":0.6,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83738446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A 47-year old Caucasian male with 7-year history of Immune Thrombocytopenic Purpura (ITP) presented with acute onset pain and purplish-blue discoloration of the left fifth toe and pleuritic chest pain. At the time of ITP diagnosis, he was positive for lupus anticoagulant (LA) and high titer of IgG anticardiolipin antibodies (aCL). However, his platelet count had previously remained stable at approximately 40,000/μL and he never required treatment. His examination was normal except for dusky cyanosis and coolness of the left fifth toe associated with extreme tenderness. Abnormal laboratory studies on admission included leukocytosis (11.610/μL), thrombocytopenia (76,000 /μL) and elevated D-dimer (770 ng/mL FEU). Cardiac enzymes, EKG and Chest X-ray were normal. A lower extremity arterial study done prior to admission was normal.
{"title":"Catastrophic antiphospholipid syndrome in a patient with immune thrombocytopenic purpura","authors":"S. John, K. McCrae","doi":"10.4999/UHOD.10095","DOIUrl":"https://doi.org/10.4999/UHOD.10095","url":null,"abstract":"A 47-year old Caucasian male with 7-year history of Immune Thrombocytopenic Purpura (ITP) presented with acute onset pain and purplish-blue discoloration of the left fifth toe and pleuritic chest pain. At the time of ITP diagnosis, he was positive for lupus anticoagulant (LA) and high titer of IgG anticardiolipin antibodies (aCL). However, his platelet count had previously remained stable at approximately 40,000/μL and he never required treatment. His examination was normal except for dusky cyanosis and coolness of the left fifth toe associated with extreme tenderness. Abnormal laboratory studies on admission included leukocytosis (11.610/μL), thrombocytopenia (76,000 /μL) and elevated D-dimer (770 ng/mL FEU). Cardiac enzymes, EKG and Chest X-ray were normal. A lower extremity arterial study done prior to admission was normal.","PeriodicalId":49402,"journal":{"name":"Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi","volume":"27 1","pages":"200-202"},"PeriodicalIF":0.6,"publicationDate":"2011-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81781822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：